Asparlas will require prior authorization for URMBT members with a Blue Cross non‑Medicare plan

For dates of service on or after Nov. 1, 2021, Asparlas™ (calasparagase pegol-mknl), HCPCS code J9118, will require prior authorization through AIM Specialty Health^®. This drug is covered under the medical benefit.

Prior authorization requirements apply when this drug is administered in an outpatient setting for UAW Retiree Medical Benefits Trust members who have a Blue Cross Blue Shield of Michigan non-Medicare plan.

How to submit authorization requests

Submit prior authorization requests to AIM using one of the following methods:

• Through the AIM ProviderPortal**
• By calling the AIM Contact Center at 1-844-377-1278

More about the authorization requirements

Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members.

For additional information on requirements related to drugs covered under the medical benefit for URMBT members with a Blue Cross non-Medicare plan, see:

• Medical oncology prior authorization list for UAW Retiree Medical Benefits Trust PPO non-Medicare members
• Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust PPO non-Medicare Members

We’ll update the appropriate drug lists to reflect the information in this message prior to the effective date.

Notes:

• Accredo manages prior authorization requests for URMBT for select medical benefit drugs that aren’t on the above two lists.
• The prior authorization requirements mentioned in this article don’t apply to the UAW Retiree Health Care Trust (group number 70605) or the UAW International Union (group number 71714) members.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.